Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28518605 | 0.91 | POLG (0.47) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL30140872 | 0.88 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL10903450 | 0.85 | POLG (0.45) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL1457065 | 0.84 | P2RY2 (0.54) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL26102705 | 0.83 | POLG (0.51) | POLGP2RY2P2RY4P2RY6POLB | |
| Phosphoric Acid SCHEMBL3635661 | 0.83 | PDE3A (0.43) | P2RY2POLBPOLA1 | |
| SCHEMBL28633711 | 0.83 | P2RY2 (0.44) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL18394211 | 0.82 | P2RY2 (0.51) | POLGP2RY2P2RY4P2RY6POLB | |
| Cyanide SCHEMBL29185226 | 0.82 | P2RY2 (0.51) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL30697338 | 0.81 | P2RY2 (0.51) | POLGP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636304-B2 | — | — | 2026-05-26 | — | — | US | disclosed |
| EP-4713450-A1 | ENGINEERED CONSTRUCTS WITH CASSETTE ARRANGEMENTS FOR INCREASED TRANSCRIPTION OF RNA PAYLOADS | Shape Therapeutics Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238584-A1 | ENGINEERED CONSTRUCTS WITH CASSETTE ARRANGEMENTS FOR INCREASED TRANSCRIPTION OF RNA PAYLOADS | SHAPE THERAPEUTICS INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240384261-A1 | METHODS, COMPOSITIONS, AND KITS FOR PREPARING SEQUENCING LIBRARY | GENEFIRST LIMITED (GB) | 2024-11-21 | — | — | US | disclosed |
| US-20240350621-A1 | DOUBLE STRANDED MRNA VACCINES | UNIV IOWA RES FOUND (US) | 2024-10-24 | — | — | US | disclosed |
| CN-117795096-A | Methods, compositions and kits for preparing sequencing libraries | 吉复生物科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4165179-A2 | METHODS OF ENRICHING FOR TARGET NUCLEIC ACID MOLECULES AND USES THEREOF | Qiagen Sciences LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2023014974-A1 | DOUBLE STRANDED MRNA VACCINES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022263807-A1 | METHODS, COMPOSITIONS, AND KITS FOR PREPARING SEQUENCING LIBRARY | GENEFIRST LIMITED (GB) | 2022-12-22 | — | — | WO | disclosed |
| US-20140171635-A1 | NOVEL HYDRAZONE-BASED AND OXIME-BASED FLUORESCENT AND CHROMOPHORIC/PRO-FLUORESCENT AND PRO-CHROMOPHORIC REAGENTS AND LINKERS | SOLULINK BIOSCIENCES, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8541555-B2 | Hydrazone-based and oxime-based fluorescent and chromophoric/pro-fluorescent and pro-chromophoric reagents and linkers | SOLULINK BIOSCIENCES, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2150858-A1 | NOVEL HYDRAZONE-BASED AND OXIME-BASED FLUORESCENT AND CHROMOPHORIC/PRO-FLUORESCENT AND PRO-CHROMOPHORIC REAGENTS AND LINKERS | Solulink, INC. (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008140452-A1 | NOVEL HYDRAZONE-BASED AND OXIME-BASED FLUORESCENT AND CHROMOPHORIC/PRO-FLUORESCENT AND PRO-CHROMOPHORIC REAGENTS AND LINKERS | SOLULINK, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080221343-A1 | Labeled biomolecules of chromophore or the fluorophore incorporated into the linker between a reactive linking moiety and a biotin molecule; proteins, nucleic acids | AUDAX PRIVATE DEBT LLC, AS AGENT | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636304-B2 | — | RNMT, RNGTT, NSUN2 | POLG 1469/4885P2RY2 2861/4885P2RY4 3525/4885 |
| US-20080221343-A1 | Labeled biomolecules of chromophore or the fluorophore incorporated into the linker between a reactive linking moiety and a biotin molecule; proteins, nucleic acids | RRP12, MRPS22, HBG2 | POLG 1353/4885P2RY2 2739/4885P2RY4 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.